Yousif Capital Management LLC Raises Stock Holdings in Becton, Dickinson and Company $BDX

Yousif Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,913 shares of the medical instruments supplier’s stock after acquiring an additional 1,260 shares during the quarter. Yousif Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $11,353,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of BDX. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after purchasing an additional 27,581 shares during the period. FORA Capital LLC bought a new position in Becton, Dickinson and Company during the first quarter valued at $3,458,000. GAMMA Investing LLC grew its holdings in Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after purchasing an additional 748 shares during the period. Finally, Ritholtz Wealth Management bought a new position in Becton, Dickinson and Company during the first quarter valued at $224,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock valued at $562,036 in the last three months. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $186.76 on Tuesday. The firm has a market capitalization of $53.53 billion, a price-to-earnings ratio of 33.59, a P/E/G ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a fifty day moving average of $190.23 and a 200 day moving average of $185.45. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Analyst Ratings Changes

Several equities analysts have weighed in on BDX shares. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective for the company. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.